Published in Oncology (Williston Park) on November 01, 2014
The evolution of liver-directed treatments for hepatic colorectal metastases. Oncology (Williston Park) (2014) 0.76
CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans. Science (2011) 7.95
Liver transplantation for hepatocellular carcinoma validation of present selection criteria in predicting outcome. Liver Transpl (2004) 1.95
Phase I trial of the antivascular agent combretastatin A4 phosphate on a 5-day schedule to patients with cancer: magnetic resonance imaging evidence for altered tumor blood flow. J Clin Oncol (2003) 1.88
Chemoembolization of intrahepatic cholangiocarcinoma with cisplatinum, doxorubicin, mitomycin C, ethiodol, and polyvinyl alcohol: a 2-center study. Cancer (2010) 1.18
A phase II and biomarker study of ramucirumab, a human monoclonal antibody targeting the VEGF receptor-2, as first-line monotherapy in patients with advanced hepatocellular cancer. Clin Cancer Res (2013) 1.16
Phase I trial of combretastatin a-4 phosphate with carboplatin. Clin Cancer Res (2005) 1.12
Systemic and targeted therapy for advanced colon cancer. Expert Rev Gastroenterol Hepatol (2008) 1.12
Chemoembolization of colorectal liver metastases with cisplatin, doxorubicin, mitomycin C, ethiodol, and polyvinyl alcohol. Cancer (2010) 0.98
Cancer immunotherapy in clinical practice -- the past, present, and future. Chin J Cancer (2014) 0.98
Neoadjuvant therapy with imatinib mesylate for locally advanced GI stromal tumor. Gastrointest Endosc (2005) 0.89
Isocitrate dehydrogenase-1 is mutated in inflammatory bowel disease-associated intestinal adenocarcinoma with low-grade tubuloglandular histology but not in sporadic intestinal adenocarcinoma. Am J Surg Pathol (2014) 0.84
Programmed Death-Ligand 1 Expression Is Common in Gastric Cancer Associated With Epstein-Barr Virus or Microsatellite Instability. Am J Surg Pathol (2016) 0.83
Lapatinib and gemcitabine for metastatic pancreatic cancer. A phase II study. Am J Clin Oncol (2011) 0.82
Molecular targeted therapy in hepatocellular carcinoma: from biology to clinical practice and future. Curr Treat Options Oncol (2014) 0.82
Developments in treatment of esophageal/gastric cancer. Curr Treat Options Oncol (2009) 0.81
Esophageal cancer in a young woman with bulimia nervosa: a case report. J Med Case Rep (2007) 0.80
Toxicity study of gemcitabine, oxaliplatin, and bevacizumab, followed by 5-fluorouracil, oxaliplatin, bevacizumab, and radiotherapy, in patients with locally advanced pancreatic cancer. Cancer Chemother Pharmacol (2013) 0.80
Hepatocellular carcinoma: prevention and therapy. Curr Oncol Rep (2011) 0.79
Oxaliplatin-associated hypersensitivity reactions: clinical presentation and management. Clin Colorectal Cancer (2006) 0.79
Phase 1 and pharmacodynamic trial of everolimus in combination with cetuximab in patients with advanced cancer. Cancer (2013) 0.78
Phase I trial of the cryptophycin analogue LY355703 administered as an intravenous infusion on a day 1 and 8 schedule every 21 days. Clin Cancer Res (2002) 0.77
Smad4 loss in esophageal adenocarcinoma is associated with an increased propensity for disease recurrence and poor survival. Am J Surg Pathol (2015) 0.77
Neoadjuvant Treatment for Surgically Resectable Metastatic Colorectal Cancer: Is There an Optimal Succession? Oncology (Williston Park) (2016) 0.76
Dose escalation study of tezacitabine in combination with cisplatin in patients with advanced cancer. Cancer (2003) 0.75
Recent advances in colorectal cancer therapy. Cancer Biol Ther (2003) 0.75
Recombinant human granulocyte macrophage colony stimulating factor in deep second-degree burn wound healing. Medicine (Baltimore) (2017) 0.75
Which questions remain unanswered following the successful development of sorafenib in hepatocellular carcinoma? Nat Clin Pract Oncol (2008) 0.75
Adjuvant therapy for gastric cancer: how negative results can help patients. J Natl Cancer Inst (2007) 0.75
Cancers of the large bowel and hepatobiliary tract. Cancer Chemother Biol Response Modif (2005) 0.75
General assessment of the patient with cancer for the interventional oncologist. J Vasc Interv Radiol (2006) 0.75
What is the reference cytotoxic regimen for advanced gastric cancer: standard versus optimal therapy? Expert Rev Anticancer Ther (2011) 0.75